Updated Jul 16, 2026
Schorno Dean L has filed 2 SEC Form 4 filings across 1 company in the last 90 days.

Dean L. Schorno is the Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals Inc, a company focused on developing small-molecule drugs for various diseases. He has been involved in the company's financial operations, contributing to its strategic direction.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 928 | $29.86 | $28K |
| 2026-06-03 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 2.2K | $12.70 | $28K |
| 2026-06-03 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 1.2K | $18.70 | $22K |
| 2026-02-19 | RIGL | RIGEL PHARMACEUTICALS INC | A — Grant or award | 20.6K | $0.00 | |
| 2026-02-12 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 3.5K | $34.62 | $123K |
| 2026-02-04 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 5.5K | $36.01 | $198K |
| 2025-12-30 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 1.7K | $18.70 | $31K |
| 2025-12-30 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 2.8K | $24.20 | $69K |
| 2025-12-30 | RIGL | RIGEL PHARMACEUTICALS INC | M — Option exercise | 2.0K | $20.00 | $40K |
Dean L. Schorno is the Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals Inc, a company focused on developing small-molecule drugs for various diseases. He has been involved in the company's financial operations, contributing to its strategic direction.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Schorno Dean L profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.